Murphy Adrianna, Jakab Melitta, McKee Martin, Richardson Erica
Centre for Health and Social Change, London School of Hygiene and Tropical Medicine, London, UK
World Health Organization Office for Europe, Regional Office for Health Systems Strengthening, Barcelona, Spain.
Health Policy Plan. 2016 Dec;31(10):1384-1390. doi: 10.1093/heapol/czw080. Epub 2016 Jun 16.
It is well known that cardiovascular diseases (CVD) are a growing cause of mortality and morbidity in low-and middle-income countries (LMIC). While hypertension (HTN), a leading risk factor for CVD, can be easily managed with widely available medicines, there is a huge gap in treatment for HTN in many LMIC. One such country is Kyrgyzstan, where HTN is a major public health concern and adherence to medication is low. The reasons for low adherence in Kyrgyzstan are not well understood, but some evidence suggests that HTN medicines may be unaffordable for low-income families, resulting in inequitable access to HTN treatment. With data from the 2010 Kyrgyzstan Integrated Household Survey, we estimate the prevalence and factors associated with adherence to HTN medication in Kyrgyzstan. We then investigate the hypothesis that affordability may be an important factor in adherence to HTN medication. Using the coarsened exact matching approach, we estimate the economic burden faced by households with at least one member with elevated blood pressure (EBP) in Kyrgyzstan and their risk of catastrophic spending on health care. We find that EBP households have significantly higher total expenditure on health, as well as on medicines, and are more likely to experience catastrophic health spending, suggesting that out-of-pocket expenditure for EBP may be prohibitively expensive for the poorest in Kyrgyzstan. Our findings also reveal a high prevalence of self-medication (i.e. purchasing and using medication without a doctor's prescription), and increased expenditure due to self-medication, among those with EBP. Our research suggests that affordability of HTN medicines may be an important factor in low adherence to treatment in Kyrgyzstan. Low affordability may be due partly to the prescription of medicines that are not reimbursable under the national drug benefit plan, but more research is needed to identify solutions to the affordability problem.
众所周知,心血管疾病(CVD)在低收入和中等收入国家(LMIC)中,正日益成为导致死亡和发病的原因。高血压(HTN)是心血管疾病的主要危险因素,虽然可以通过广泛可得的药物轻松控制,但许多低收入和中等收入国家在高血压治疗方面存在巨大差距。吉尔吉斯斯坦就是这样一个国家,高血压是主要的公共卫生问题,且药物依从性较低。吉尔吉斯斯坦药物依从性低的原因尚不完全清楚,但一些证据表明,低收入家庭可能买不起高血压药物,导致高血压治疗的可及性不公平。利用2010年吉尔吉斯斯坦综合家庭调查的数据,我们估计了吉尔吉斯斯坦高血压药物依从性的患病率及相关因素。然后,我们研究了可负担性可能是高血压药物依从性的一个重要因素这一假设。使用粗化精确匹配方法,我们估计了吉尔吉斯斯坦至少有一名成员血压升高(EBP)的家庭所面临的经济负担及其医疗保健灾难性支出的风险。我们发现,血压升高的家庭在医疗保健以及药品方面的总支出显著更高,并且更有可能经历灾难性医疗支出,这表明血压升高人群的自付费用对于吉尔吉斯斯坦最贫困的人群来说可能过高。我们的研究结果还显示,血压升高人群中自我药疗(即无医生处方购买和使用药物)的患病率很高,且自我药疗导致支出增加。我们的研究表明,高血压药物的可负担性可能是吉尔吉斯斯坦治疗依从性低的一个重要因素。可负担性低可能部分归因于国家药品福利计划不报销的药物处方,但需要更多研究来确定解决可负担性问题的办法。